| 99283 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a low level of medical decision making. | 241 | 700 | 2,400 | $80 | $1.2M |
| 99284 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making. | 206 | 740 | 2,180 | $70 | $1.1M |
| J9271 | Injection, pembrolizumab, 1 mg | 1 | 10 | 630 | $1,300 | $977.3K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 5 | 10 | 710 | $850 | $915.3K |
| 99285 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a high level of medical decision making. | 110 | 660 | 1,900 | $70 | $743.6K |
| 77386 | Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex | 1 | 10 | 1,510 | $190 | $692.6K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 40 | 40 | 320 | $100 | $620K |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 1 | 10 | 660 | $780 | $515.2K |
| J9306 | Injection, pertuzumab, 1 mg | 2 | 10 | 590 | $790 | $470.3K |
| 99282 | The provider sees a patient for an emergency department visit involving evaluation and management (E/M). The visit involves a straightforward level of medical decision making. | 7 | 320 | 1,970 | $90 | $463.1K |